EU body considering Astrazeneca vaccine
Could receive approval as early as Jan. 29
LONDON – The European Medicines Agency said Tuesday that Astrazeneca and Oxford University have submitted an application for their COVID-19 vaccine to be licensed across the European Union.
The EU regulator said it received a request for the vaccine to be greenlighted under an expedited process and that it could be approved by Jan. 29 “provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete.”
The EMA, the drugs agency for the 27-nation EU, has already approved two other coronavirus vaccines, one made by American drugmaker Pfizer and Germany’s Biontech and another made by U.S. biotechnology company Moderna.
Switzerland approved the Moderna vaccine on Tuesday and plans to immunize about 4% of its population using that and the Pfizer-biontech shot.
Britain gave its approval to the Oxford-astrazeneca vaccine last month and has been using it. India approved it this month.
As part of its strategy to obtain as many different COVID-19 vaccines as possible for Europeans, the EU said it had concluded early talks with French biotech company Valneva to secure up to 60 million doses of vaccine.
Valneva previously signed a deal with Britain to provide tens of millions of doses of its shot, which is developed using similar technology to that used to make flu vaccines. The EU has sealed six vaccine contracts for up to 2 billion doses, many more than are necessary to cover its population of approximately 450 million.
The Oxford-astrazeneca vaccine is expected to be a key vaccine for many countries because of its low cost, availability and ease of use. It can be kept in refrigerators rather than the ultra-cold storage that the Pfizer vaccine requires. The company has said it will sell it for $2.50 a dose and plans to make up to 3 billion doses by the end of 2021.
Researchers say the Oxford-astrazeneca vaccine protected against disease in 62% of those given two full doses and in 90% of those initially given a half dose because of a manufacturing error. However, the second group included only 2,741 people – too few to be conclusive.
Questions also remain about how well the vaccine protects older people.